iNtRON is finalizing the SAL200 Tech Transfer
/PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com) has announced today that the Tech Transfer process of SAL200, endolysin-based new...
Stay updated with breaking news from Tech Transfer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com) has announced today that the Tech Transfer process of SAL200, endolysin-based new...
The director of NIST’s Manufacturing Extension Partnership looks ahead to the most transformative technology taking hold in the manufacturing world.
Fitzsimons Innovation Community continues to expand on it's already massive campus in 2023 and beyond.
Frankfurt, Germany (PRWEB) November 30, 2022 -- about:blank [PharmaLex Group __title__ null]’s about:blank [Biopharma Excellence __title__ null] service line,
A drug compound attacks hard-to-treat prostate cancer on several fronts, according to a Washington University School of Medicine in St. Louis study in mice and human cells. It triggers immune cells to attack, helps the immune cells penetrate the tumor and cuts off the tumor’s ability to burn testosterone as fuel.